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Nursing home placement in the donepezil and memantine in moderate to severe Alzheimer's 
disease (DOMINO) trial: secondary and post-hoc analyses of a randomised trial 
 
Structured abstract 
 
Background: Observational studies have suggested delay in nursing home placement (NHP) with 
dementia drug treatment, but an earlier randomised trial in patients with mild to moderate 
Alzheimer’s disease (AD) showed no effect. We investigated the effects of continuing or 
discontinuing donepezil and starting memantine on subsequent NHP in moderate to severe AD.  
Methods: In the DOMINO trial (ISRCTN49545034) 295 community living patients with moderate to 
severe AD recruited from 15 centres in England and Scotland from February 2008 to March 2010 
were randomised with double-blind placebo-control to continue donepezil (73), discontinue 
donepezil (73), discontinue donepezil and start memantine (76), or continue donepezil and start 
memantine (73) for 52 weeks. After 52 weeks choice of treatment was left to participants and their 
physicians. Place of residence was recorded at outcomes assessment points during the first 52 weeks 
of the trial and subsequently every 26 weeks for a further 3 years. Nursing home placement was an 
irreversible move from independent accommodation to a residential caring facility and was a 
secondary trial endpoint. Analyses restricted to the risk of placement in the first year of follow-up 
were post-hoc. 
Findings: 162 patients (55%) underwent NHP within 4 years of randomisation. Numbers of NHPs 
were similar for all arms (36 in patients who continued donepezil, 42 who discontinued donepezil, 41 
who discontinued donepezil and started memantine, and 43 who continued donepezil and started 
memantine). There was significant (p=0.010) heterogeneity of treatment effect over time with 
significantly more NHPs in the donepezil discontinuation group during the first year (HR 2.09 (95% 
CI, 1.29 to 3.39)) and no difference later (HR 0.89 (95% CI, 0.58 to 1.35)). Subsequent analyses 
focussed on the first year of the trial and on donepezil only were post-hoc. 1-year NHP risk was 17% 
higher (95% CI 6% to 28%) in patients allocated to discontinue donepezil compared to continuing 
donepezil. There was no effect of starting memantine compared to no memantine during the first 
year (HR 0.92 (95% CI 0.58 to 1.45)) or later (HR 1.23 (95% CI 0.81 to 1.87)); difference in 1-year NHP 
risk 1% (95% CI -12% to 10%). 
 
Interpretation: Withdrawing donepezil in patients with moderate to severe AD increased the risk of 
NHP during 12 months of trial treatment, but made no difference to NHP over 4 years of follow-up. 
Decisions to stop or continue drug treatment at this stage should be informed by potential risks of 
withdrawal, even if the perceived benefits of continued treatment are not clear.    
Funding: Funded by the U.K. Medical Research Council and the Alzheimer’s Society. 
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Introduction 
Reasons for nursing home placement (NHP) in Alzheimer’s disease (AD) are complex, involving 
patient and caregiver characteristics as well as the cultural and social environment. White ethnicity, 
impairments in cognition and activities of daily living, behavioural problems and increased caregiver 
age and burden all predict nursing home placement in AD.1 Economic costs in dementia increase 
markedly with disease severity with NHP contributing substantially to total support costs in severe 
dementia. Whether cholinesterase inhibitors and memantine can delay the point at which AD 
patients make the transition to permanent residential care is controversial. AD2000, the only 
randomised controlled double-blind trial to directly address this question for donepezil was 
negative.2 Observational studies, following patients who have participated in double-blind or open 
trials or received open label treatment with tacrine,3 donepezil,4 tacrine, donepezil or rivastigmine,5,6 
galantamine,7 or memantine combined with a cholinesterase inhibitor8 have reported positive 
results. These studies have been criticised as they have not involved randomisation, placebo-control 
or blinding of treatment allocation.9-12 The socioeconomic implications of resolving this controversy 
are clear. Models based on assumptions that the drugs can delay placement indicate large societal 
and healthcare cost savings.13  
We have previously shown that continued treatment with donepezil in patients with moderate to 
severe AD is associated with cognitive and functional benefits over the course of 12 months 
compared to tapering and discontinuing.14 It could be argued that modest cognitive and functional 
treatment benefits in moderate to severe dementia have only limited impact on the lives of patients 
and caregivers. An important secondary objective of our trial was to investigate whether continuing 
a drug treatment that improved dementia symptoms would also delay NHP in an AD population who 
had already reached the severity point at which independent home living was likely to be 
compromised. Trial participants have completed 4 years of double-blind follow-up and we now 
report how treatment allocation affected subsequent permanent NHP.  
    
Methods 
Study design and participants 
The Donepezil and Memantine in Moderate to Severe Alzheimer’s Disease (DOMINO) study 
(ISRCTN49545034) was a multicentre (15 secondary care Memory Services in England and Scotland), 
double-blind, placebo-controlled, clinical trial with a two-by-two factorial design.15 Eligible 
participants met standardized criteria16 for probable or possible moderate or severe AD, had been 
prescribed donepezil continuously for at least 3 months with a dose of 10 mg for at least the 
previous 6 weeks, and had a score between 5 and 13 on the Standardised Mini-Mental State 
Examination.17  
Randomisation and masking 
The first 80 participants were assigned with the use of a prepared unrestricted randomised list of 
assignments to ensure allocation concealment.18 Thereafter, participants were randomly assigned to 
one of four treatment groups for 12 months: continuation of donepezil 10 mg per day, with placebo 
memantine; discontinuation of donepezil (following 4 weeks of treatment with 5 mg), with placebo 
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memantine; discontinuation of donepezil and initiation of treatment with memantine 20 mg per 
day; or continuation of donepezil 10 mg per day and initiation of memantine 20 mg per day. 
Treatment assignments were made by the U.K. Medical Research Council Clinical Trials Unit with the 
use of randomized minimization.18 Groups were stratified according to centre (among the 15 
participating centres), duration of donepezil treatment before entry (3 to 6 months vs. >6 months), 
baseline SMMSE score (5 to 9 vs. 10 to 13), and age (<60 years, 60 to 74 years, or >74 years). 
Patients, caregivers, clinicians, outcome assessors, and investigators were blinded to treatment 
assignments.  
Outcome measures and trial procedures 
The primary outcomes of the trial were scores on the SMMSE and on the caregiver-rated Bristol 
Activities of Daily Living Scale. Results on these outcomes, along with neuropsychiatric symptoms, 
participant quality of life and caregiver psychological distress outcomes during completion of the 52 
week intervention have been reported in an earlier paper.14 In addition, the Client Service Receipt 
Inventory (CSRI)19 was completed for the 52 weeks of trial treatment. In the CSRI, the following are 
classified as NHP: care home providing nursing care, care home providing personal care, dual 
registered home (providing both personal and nursing care), acute psychiatric ward, general medical 
ward, rehabilitation ward) and the following as non-NHP: owner occupied house/flat, privately 
rented house/flat, house/flat rented from housing association or local authority, sheltered/warden 
controlled housing, extra care housing. The CSRI captured the patient’s “usual place of residence” 
since the last assessment, together with the number of days spent living in other locations. When 
the “usual place of residence” had changed to a NHP from the previous visit, the date of NHP was 
estimated as the number of days lived outside NHP since the previous assessment date subtracted 
from the assessment date at which the change was reported. Over the following 3 years, the 
caregiver was contacted by telephone every 26 weeks and asked whether the participant was still 
living at home or had moved to live permanently in a residential or nursing home, and if such a move 
had occurred, the date of transition. The definition of NHP and the date of transition to NHP 
remained the same throughout the study, despite the change in the method of data collection. The 
original planned sample size was 800, but was adjusted to 430 due to reduced standard deviations 
for the primary outcomes from an interim blinded analysis of trial data. The trial was designed with 
at least 90% power for the primary outcomes, but was not powered to show differences on time to 
NHP. Trial recruitment was conducted between 11 February 2008 and 5 March 2010 and the last 
participant completed follow-up in March 2014. 
 
Study oversight 
The study was overseen by King’s College London and was funded by the U.K. Medical Research 
Council and the Alzheimer’s Society. Full ethical approval was received from the Scotland A 
Multicentre Research Ethics Committee. Agreement in writing to take part in the study was obtained 
from participants if they had capacity to give informed consent, and the main caregivers gave 
written consent for their own involvement and assent for the patients’ participation. The 
corresponding author (RH) vouches for the accuracy and completeness of the data and for the 
fidelity of the study to the protocol. All authors had full access to all of the data in the study and can 
take responsibility for the integrity of the data and the accuracy of the data analysis. Data sharing: 
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patient level data (without date of birth or recruiting centre) and the full dataset are available with 
open access from the corresponding author. Consent was not obtained from participants for data 
sharing but the presented data are anonymised and risk of identification is low. 
Role of the funding source 
The UK Medical Research Council and Alzheimer’s Society who funded the trial had no role in the 
study design, the collection, analysis or interpretation of data, the writing of the report or the 
decision to submit for publication. Pfizer-Eisai and Lundbeck donated drug and placebo supplies but 
had no involvement in the design or conduct of the study or the analysis or reporting of the data. All 
authors had full access to all of the study data and Professor Howard had final responsibility for 
submitting the paper for publication. 
Statistical analysis 
Following the pre-specified statistical analysis plan, time to NHP was analysed using stratified log-
rank (using randomisation minimisation factors as strata) and Cox proportional hazards regression 
with patients who died or who withdrew from follow-up before NHP censored at date of death or 
withdrawal. The assumption of proportion hazards was tested using the Shoenfeld residuals with 
ranking of follow-up time. Since this was a secondary endpoint for the trial, the statistical analysis 
plan did not include any pre-specified analyses in the event of non-proportional hazards, when the 
log-rank test has reduced power to detect differences and standard Cox regression is inappropriate. 
Subsequent analyses were not pre-specified in the analysis plan since the presence of non-
proportional hazards was not anticipated. For situations with evidence of non-proportional hazards 
(p < 0.05), follow-up was split into distinct periods with hazards assumed to be proportional within 
each period (piecewise proportional hazards modelling). Regression models with different time 
period splits were compared using the Akaike Information Criterion (AIC). Probability of NHP by time 
after randomisation was calculated from the Kaplan-Meier survivor function with 95% confidence 
intervals. Differences in centiles of survival time and probability of NHP between groups were 
calculated with 95% bias-corrected bootstrap confidence intervals using 1000 bootstrap replications. 
The log-rank statistic was calculated for each strata and tabulated with event rate ratios using 
methods previously described20 to explore the effect of stratification. 
The protocol and statistical analysis plan pre-specified that death before NHP would be considered 
as a censoring event in the same way as withdrawal or loss from follow-up. However, NHP may have 
been more likely in patients who died compared to those who withdrew from follow-up had the 
patients not died or withdrawn respectively. We therefore conducted two additional sensitivity 
analyses: 1) considering all deaths as NHP events at the time of death (equivalent to the composite 
endpoint of death or NHP) and 2) a competing risks analysis21 modelling the sub-hazard function of 
NHP in the presence of the competing risk of death.  
The following patient baseline covariates were evaluated for association with time to NHP in the 
regression model: age, gender, prior duration of donepezil treatment, centre, ethnicity, gender of 
carer, relationship of carer, whether patient lives with carer, sMMSE, BADLS, NPI, DEMQOL-proxy, 
EQ-5D health state, and NPI subscales of  delusions, hallucinations, agitation/aggression and 
irritability/lability. Covariates were only considered as predictors if the treatment-adjusted effect 
was significant at the 5% level in separate univariable models. 
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In addition, parametric models were used to describe how the underlying risk of NHP changes with 
time. The following standard parametric models were fitted to the data: Weibull, generalized 
gamma, log-normal, log-logistic and Gompertz. Flexible parametric survival models do not assume 
an underlying log-linear relationship with time or with hazard and allow a more flexible fully 
parametric modelling approach.22 These were compared with standard parametric models, with the 
best fitting model chosen using the AIC. 
 
Results 
Of the 295 patients randomised into the trial, 162 (55%) had NHP within 4 years of randomisation. 
Table 1 summarises the patient baseline characteristics and Table 2 time to NHP in each of the four 
treatment groups.  Figure 1 shows the patient flowchart. 
Primary analysis (pre-specified) 
There was evidence of a difference in time to NHP between discontinuing and continuing donepezil 
(stratified log rank test, p=0.022), although non-significant in the un-stratified analysis (p=0.100). 
There was no evidence for an interaction (p=0.168 stratified, p=0.446 un-stratified) and no benefit of 
starting memantine (p=0.719 stratified, p=0.628 un-stratified). Subsequent analyses therefore only 
consider the effect of discontinuing donepezil. Figure 2A shows the Kaplan-Meier survival curve of 
cumulative probability of NHP by treatment arm. 
The 25th percentile of time to NHP was greater in patients continuing donepezil, 12.7 months (95% 
CI, 10.4 to 14.0), as compared to 8.9 (95% CI, 5.5 to 10.1) months for patients discontinuing 
donepezil, a difference of 3.8 months (95% CI, 1.5 to 7.0). There was no difference in median time to 
NHP: 21.9 months (95% CI, 16.9 to 29.1) and 16.7 months (95% CI, 12.7 to 22.1) respectively.  
Figure 3 shows the log rank statistics and event rate ratio for each strata and also by time period of 
NHP from randomisation, by whether patients were allocated to continue or discontinue donepezil.  
There was clear evidence of non-proportional hazards (p=0.01, Figure 2B) indicating that the overall 
hazard ratio of discontinuing compared to continuing donepezil was not an appropriate summary 
measure as the effect of discontinuing donepezil changed with time. Kaplan Meier survival curves 
appeared to separate over the first 12 months and were parallel thereafter. Subsequent results are 
based on analyses that were not pre-specified in the analysis plan since non-proportional hazards 
was not anticipated.  
Piecewise modelling in the presence of non-proportional hazards 
Splitting follow-up time at only 12 months resulted in better model fit, and lower AIC, than splits at 
any combination of 6, 12 and 24 months (data not shown). Discontinuing donepezil more than 
doubled the (instantaneous) probability of NHP over the first year (hazard ratio 2.09 (95% CI, 1.29 to 
3.39)) compared to continuing donepezil (Table 3). This benefit was maintained after 12 months 
with curves remaining approximately equidistant (hazard ratio 0.89, (95% CI, 0.58 to 1.35)). This 
hazard ratio after 12 months should be interpreted with caution due to selection bias;23 this is 
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estimated from the sub-group of patients without NHP by 12 months which included more patients 
that had discontinued than had continued donepezil. 
Discontinuing donepezil treatment increased the probability of NHP over the first 6 months from 
0.06 to 0.19 (difference 0.13, 95% CI, 0.04 to 0.21) and over the first 12 months from 0.20 to 0.37 
(difference 0.17, 95% CI, 0.06 to 0.28), see Table 3. This indicates a number needed to treat of 5.88 
patients for 12 months to prevent 1 NHP. 
Patients who lived with their carers at baseline had a lower instantaneous risk of NHP throughout 
follow-up as compared to those that didn’t live with their carers (p=0.013, hazard ratio 0.63, 95% CI, 
0.44 to 0.89). This effect did not differ by treatment arm (p=0.48, test for interaction) and no other 
baseline covariates tested were associated with NHP (data not shown). 
Sensitivity analyses 
66 patients died before NHP with a further 26 deaths reported after NHP. There was no evidence for 
differences in time to death between arms (p=0.816 stratified, p=0.971 un-stratified). In both the 
analysis of the composite endpoint of death or NHP and the competing risks analysis, the results 
were consistent with no evidence of an effect of memantine and evidence of a large benefit with 
donepezil over the first 12 months that was maintained after 12 months (data not shown).  
Parametric survival models 
None of the standard parametric models provided a good fit for the data, unlike the flexible 
parametric survival model. The preferred model was a PH(1) model with 3 degrees of freedom for 
the time varying covariate of donepezil (active vs placebo). Figure 4 shows the fitted hazard function 
(Figure 4A) and survivor function (Figure 4B) from this model showing how the underlying risk of 
NHP changes with time. The risk of NHP in patients discontinuing donepezil is high in the first 
months, with a peak around 6 months and steadily declining thereafter. The risk of NHP in patients 
continuing donepezil is lower over the first 12 months, with the peak not occurring until after 12 
months and steadily declining after this. There is clear separation of the curves over the first 6-12 
months with the risk of NHP approximately equal for both groups from 12 months onwards. 
 
 
Discussion 
This is the first randomised double-blind study to demonstrate a significant effect of dementia drug 
treatment on NHP. We found that discontinuing donepezil treatment in patients with moderate to 
severe AD was associated with a doubling of the instantaneous risk of placement to nursing homes 
over 12 months. There was no significant difference in the risk of placement at later follow-up points 
and there was no effect of starting memantine treatment, either singly or when combined with 
donepezil, at any point in the trial. We acknowledge that the comparison of time to NHP was a 
secondary objective of the DOMINO trial and that the analysis restricted to the first 12 months was 
not pre-specified in the statistical analysis plan. These results should therefore be considered 
exploratory and ideally would need to be confirmed in future studies. It is recommended that 
9 
 
restricted mean survival time may be a more appropriate treatment effect measure than (average) 
hazard ratio in the presence of non-proportional hazards. However, given the apparent 
disadvantages of withdrawing cholinesterase inhibitor treatment,14 data from further double-blind 
trials are unlikely to become available.  
The cholinesterase inhibitors are symptomatic treatments for AD and are not disease-modifying. 
How might symptom worsening, associated with withdrawal of donepezil, increase risk of nursing 
home placement? Yaffe and colleagues showed that impairment in activities of daily living (ADLs) 
was a more important predictor of NHP than cognitive impairment.1 In their study, Kaplan-Meier 
rates for NHP over 1 year were 24% for patients with a Mini-Mental State Examination (MMSE)24 
score of 15 to 20, and 26% for MMSE score of <15, but 15% for those who were ADL independent 
and 25% for patients with one or more ADL dependency.1 Analysis of data from a long-term clinical 
trial showed that, although baseline ADL score influenced risk for and time to NHP, it was decline in 
ADL that most strongly predicted placement.25 Withdrawal from donepezil treatment in the 
DOMINO trial was associated with an average 3 point Bristol Activities of Daily Living Scale (BADLS)26 
disadvantage during the 12 month intervention period.14 Given the established impact of ADL status 
and loss of ADLs upon the risk of NHP,1,25 it is most likely that the ADL worsening seen when patients 
were withdrawn from donepezil in the trial represents the mechanism for earlier NHP. 
Since NHP is influenced by social and living circumstances, preferences and values,1 and that an 
earlier RCT conducted by some of the authors of the current study reached unambiguously negative 
conclusions,2 is it truly plausible that donepezil treatment could significantly affect NHP? There are 
three important differences between the AD20002 and DOMINO14 trials that might have relevance in 
consideration of this point. First, DOMINO examined the effects of withdrawing established 
donepezil treatment27 while AD2000 investigated the effects of commencing treatment. Second, the 
mean MMSE score of patients entering AD2000 was 19 points, and for DOMINO 9 points. The 
participant populations were therefore very different in terms of dementia severity and proximity to 
the time of greatest risk of NHP. Only 9% of donepezil and 14% of placebo treated AD2000 patients 
moved to NHP in the first 12 months and it is possible that NHP was too rare an event in AD2000 for 
a treatment effect to be seen. Third, the magnitude of treatment effects on cognition and ADLs were 
greater in DOMINO than AD2000. Over 2 years, AD2000 participants who received donepezil were 
on average 0.8 MMSE points and 1.0 BADLS points better than those on placebo,2 while the average 
12-month drug-placebo differences for donepezil in DOMINO were 1.9 SMMSE points and 3.0 BADLS 
points.14 Although they showed no overall effect on NHP, the AD2000 authors did find that BADLS 
and Neuropsychiatric Inventory28 scores, and age were strong independent predictors of NHP, and 
using a multivariate model, predicted that a 2 to 3 point improvement in BADLS with donepezil 
would have reduced the rate of institutionalisation in their sample by 10% in the first year. 
A limitation of our data is that we did not collect information about dementia drug use after the 52 
weeks of double-blind trial treatment was completed. Participants were not routinely unblinded 
following completion of the trial drug treatment and decisions about their subsequent treatment 
were made by their responsible clinician. A second limitation relates to our examination of follow-up 
periods. In the pre-specified primary analysis, as described in the Protocol, considering the whole 
follow-up period (using a stratified log rank test), there was a statistically significant effect for 
continuing donepezil as compared to withdrawing and substituting placebo (p =0.022). The 
piecewise modelling, however, considering time to NHP in the first 12 months that we carried out 
10 
 
thereafter was not a pre-specified analysis and this should be borne in mind in interpretation of the 
results. Further, withdrawal from study drug was significantly more common among participants 
assigned to discontinue donepezil than those assigned to continue14 and this should be borne in 
mind in consideration of the results. A strength of our data was that DOMINO was designed as a 
pragmatic study, to answer questions about the treatment of typical AD patients within 15 different 
public health services for people with dementia across England and Scotland, and the inclusion and 
exclusion criteria were relatively unselective, both to facilitate participant recruitment and to ensure 
study generalisability. 
The economic benefits of preventing or delaying NHP in AD are large and clear,13,29 as in the UK this 
reduces costs to the public purse, even if it increases the imputed costs of unpaid care, but there 
would also be important positive effects upon patient quality of life. A survey of caregivers indicated 
that they regarded NHP as a major negative determinant of quality of life, with more than two-thirds 
rating delaying NHP as “extremely important” or “very important” in maintaining quality of life.30 
The decrease in the quality of life for people with dementia associated with NHP, along with societal 
costs of such placements have driven national policy in England to maintain people with dementia 
within their own households for as long as is possible. Our data suggest that withdrawing 
cholinesterase inhibitor treatment in moderate to severe AD brings forward the timing of NHP 
during the following 52 weeks, but that this effect did not operate at later points during 4-year 
follow-up. This would be consistent with the effects of modest symptomatic improvement in 
cognition and function associated with these drugs.     
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Figure 1. Patient flowchart.
 
  
318 patients assessed for 
eligibility 
295 randomised 
73 assigned to have 
donepezil continued and 
active memantine added 
(Group 4) 
Year 1 (73 at risk) 
13(18%) NHP 
7(10%) died 
8(11%) withdrawn  
Year 2 (45 at risk) 
17(38%) NHP 
5(11%) died 
0 withdrawn  
Year 3 (23 at risk) 
6(26%) NHP 
3(13%) died 
1(4%) withdrawn  
Year 4 (13 at risk) 
7(54%) NHP 
2(15%) died 
0 withdrawn  
4(31%) no NHP at end of 
follow-up 
73 assigned to have 
donepezil continued and 
placebo memantine 
added (Group 3) 
Year 1 (73 at risk) 
13(18%) NHP 
13(18%) died 
5(7%) withdrawn  
Year 2 (42 at risk) 
16(38%) NHP 
2(5%) died 
1(2%) withdrawn  
Year 3 (23 at risk) 
4(17%) NHP 
3(13%) died 
0 withdrawn  
Year 4 (16 at risk) 
3(19%) NHP 
2(13%) died 
0 withdrawn  
11(69%) no NHP at end 
of follow-up  
76 assigned to have 
donepezil discontinued 
and active memantine 
added (Group 2) 
Year 1 (76 at risk) 
22(29%) NHP 
7(9%) died 
15(20%) withdrawn  
Year 2 (32 at risk) 
14(44%) NHP 
4(13%) died 
0 withdrawn  
Year 3 (14 at risk) 
1(7%) NHP 
0 died 
0 withdrawn  
Year 4 (13 at risk) 
4(31%) NHP 
1(8%) died 
0 withdrawn  
8(62%) no NHP at end of 
follow-up  
73 assigned to have 
donepezil discontinued 
and placebo memantine 
added (Group 1) 
Year 1 (73 at risk) 
24(33%) NHP 
9(12%) died 
6(8%) withdrawn  
Year 2 (34 at risk) 
12(35%) NHP 
4(12%) died 
1(3%) withdrawn  
Year 3 (17 at risk) 
4(24%) NHP 
2(12%) died 
0 withdrawn  
Year 4 (11 at risk) 
2(18%) NHP 
2(18%) died 
0 withdrawn  
7(64%) no NHP at end of 
follow-up 
23 were excluded 
* 2 declined to participate 
* 21 did not meet inclusion criteria 
** 19 inadmissible sMMSE 
** 1 no diagnosis of AD 
** 1 not maintained on 10mg donepezil for 6 
weeks 
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Figure 2:  Kaplan-Meier curve of cumulative probability of NHP (A) by treatment group, (B) by 
discontinue vs continue donepezil and (C) by adding memantine. Patients were allocated to 
discontinue donepezil (group 1), discontinue donepezil and start memantine, continue donepezil 
(group 3), or continue donepezil and start memantine (group 4) for 52 weeks. 
A 
 
  
16 
 
B 
 
C. 
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Figure 3. Comparison of the effect of discontinuing with continuing donepezil on risk of NHP in 
each category of randomisation minimisation strata and time period from randomisation. O-E 
refers to the difference between the Observed and Expected events within each strata and is the 
log-rank statistic. The comparison of the effect of memantine is not shown since there was no 
overall difference on event rate, stratified or un-stratified.  
*All excluding time from randomisation.  
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Figure 4: Graphs of fitted hazard (A) and cumulative probability of NHP (B) for flexible parametric 
survival model (dashed lines) with regions showing 95% confidence regions. Solid lines show fitted 
estimates and dashed line in B shows Kaplan-Meier (KM) non-parametric estimates. This was a 
post-hoc analysis to describe how the hazard (instantaneous risk) of NHP changes over time.  
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Table 1. Patient baseline characteristics by treatment arm.  
 
Discontinue donepezil Continue donepezil 
Total Add placebo 
memantine 
Add memantine 
Add placebo 
memantine 
Add memantine 
Total randomised 73 76 73 73 295 
Age in years at baseline / Mean (SD) 77.7 (8.0) 76.2 (8.9) 77.2 (7.5) 77.5 (9.0) 77.1 (8.4) 
Male / N (%) 26 (36%) 30 (39%) 22 (30%) 24 (33%) 102 (35%) 
Ethnicity 
N (%) 
White 71 (97%) 73 (96%) 69 (95%) 67 (92%) 280 (95%) 
Black 2 (3%) 2 (3%) 1 (1%) 4 (5%) 9 (3%) 
Other 0 1 (1%) 3 (4%) 2 (3%) 6 (2%) 
Donepezil duration 
prior to randomisation / 
N (%) 
3-<6Months 3 (4%) 4 (5%) 3 (4%) 4 (5%) 14 (5%) 
6- <12 Months 8 (11%) 4 (5%) 9 (12%) 3 (4%) 24 (8%) 
12+ Months 62 (85%) 68 (89%) 61 (84%) 66 (90%) 257 (87%) 
Male carer / N(%) 36 (49%) 31 (41%) 36 (49%) 34 (47%) 137 (46%) 
Carer lives with patient / N(%) 65 (89%) 58 (76%) 58 (79%) 53 (73%) 234 (79%) 
Relationship of 
carer/ N(%) 
Spouse or partner 56 (77%) 49 (64%) 41 (56%) 43 (59%) 189 (64%) 
Son or daughter 15 (21%) 18 (24%) 30 (41%) 28 (38%) 91 (31%) 
Other relative 0 7 (9%) 1 (1%) 1 (1%) 9 (3%) 
Friend or neighbour 0 2 (3%) 0 0 2 (1%) 
Paid Carer 2 (3%) 0 1 (1%) 1 (1%) 4 (1%) 
Mean (SD) sMMSE at baseline 9.1 (2.4) 9.2 (2.5) 9.0 (2.8) 9.1 (2.6) 9.1 (2.6) 
Mean (SD) BADLS at baseline 28.6 (8.9) 27.1 (9.0) 28.2 (9.0) 26.9 (9.8) 27.7 (9.2) 
Mean (SD) NPI at baseline 22.9 (17.0) 23.1 (16.2) 22.3 (16.7) 20.3 (14.4) 22.2 (16.1) 
Standardised Mini-Mental State Examination (sMMSE, range 0 to 30, higher scores indicate better cognitive function); Bristol Activities of Daily Living Scale 
(BADLS, range 0 to 60, higher scores indicate greater functional impairment); Neuropsychiatric Inventory (NPI, range 0 to 144, higher scores indicate 
increased behavioural and psychological symptoms) 
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Table 2. Summary of time to NHP and deaths by treatment arm. 
 
Discontinue donepezil Continue donepezil 
Add placebo 
memantine 
Add memantine 
Add placebo 
memantine 
Add memantine 
Total follow-up time at risk (person-years) 97.0 100.7 121.0 117.8 
Number of NHP events 42 (58%) 41 (54%) 36 (49%) 43 (59%) 
Observed NHP Rate per 10 person-years 
(95% CI) 
4.33 (3.20, 5.86) 4.07 (3.00, 5.53) 2.98 (2.15, 4.13) 3.65 (2.71, 4.92) 
Centiles of time to NHP 
in months (95% CI) 
25% 8.9 (2.6, 11.1) 9.0 (6.0, 12.0) 12.7 (9.5, 14.0) 12.8 (8.9, 15.2) 
50% (median) 16.7 (11.1, 26.2) 16.6 (12.0, 22.2) 21.9 (14.0, 40.9) 20.7 (15.2, 30.0) 
Probability of NHP by 
time after randomisation 
(95% CI) 
6 months 0.23 (0.15, 0.35) 0.15 (0.08, 0.26) 0.07 (0.03, 0.16) 0.06 (0.02, 0.15) 
12 months 0.37 (0.27, 0.50) 0.37 (0.26, 0.51) 0.21 (0.12, 0.33) 0.20 (0.12, 0.32) 
24 months 0.61 (0.48, 0.73) 0.66 (0.53, 0.79) 0.53 (0.40, 0.66) 0.53 (0.40, 0.67) 
36 months 0.71 (0.58, 0.83) 0.69 (0.56, 0.81) 0.62 (0.48, 0.75) 0.65 (0.53, 0.78) 
48 months 0.77 (0.64, 0.88) 0.76 (0.63, 0.87) 0.69 (0.56, 0.2) 0.86 (0.73, 0.95) 
Deaths before NHP  17 (23%)   12 (16%)   20 (27%)   17 (23%)  
Deaths reported after NHP    4 (5%)     7 (9%)    7 (10%)    8 (11%)  
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Table 3: Summary of time to NHP by donepezil group, and separately by memantine group. The analysis separated in 0-12 and 12-48 month periods was 
not a planned analysis, but is appropriate in the presence of non-proportional hazards.   
 
Continue 
donepezil 
Discontinue 
donepezil 
Difference 
between groups 
Add placebo 
memantine 
Add memantine 
Difference 
between groups 
Total randomised 146 149  149 146  
Overall 
Time at risk (years) 238.8 197.8  218.0 218.6  
Number of NHP events 79 83  78 84  
NHP Rate (per 10 years) 3.31 (2.65, 4.12) 4.20 (3.38, 5.20)  3.58 (2.87, 4.47) 3.84 (3.10, 4.76)  
Hazard ratio (95% CI) Reference 1.29 (0.95, 1.76)  Reference 1.08 (0.79, 1.47)  
Proportional hazards p = 0.010   p = 0.068   
0 – 12 
months 
Time at risk (years) 120.5 104.2  109.8 114.9  
Number of NHP events 26 46  37 35  
NHP Rate (per 10 years) 2.16 (1.47, 3.17) 4.42 (3.31, 5.89)  3.37 (2.44, 4.65) 3.05 (2.19, 4.24)  
Hazard ratio (95% CI) Reference 2.09 (1.29, 3.39)  Reference 0.92 (0.58, 1.45)  
12 – 48 
months 
Time at risk (years) 118.3 93.6  108.2 103.7  
Number of NHP events 53 37  41 49  
NHP Rate (per 10 years) 4.48 (3.42, 5.86) 3.95 (2.87, 5.46)  3.79 (2.79, 5.15) 4.73 (3.57, 6.25)  
Hazard ratio (95% CI) Reference 0.89 (0.58, 1.35)  Reference 1.23 (0.81, 1.87)  
Centiles of time to NHP 
in months (95% CI) 
25th 12.7 (10.4, 14.0) 8.9 (5.5, 10.1)    -3.8 (-7.0, -1.5)  10.1 (8.9, 12.6) 11.2 (8.9, 12.8)      1.1 (-2.7, 4.2)  
Median 21.9 (16.9, 29.1) 16.7 (12.7, 22.1)    -5.1 (-12.7, 2.6)  17.5 (14.0, 26.2) 19.6 (15.1, 24.1)      2.2 (-5.5, 9.3)  
Probability of NHP by 
time after 
randomisation, Kaplan-
Meier estimates 
(95% CI) 
6 months 0.06 (0.03, 0.12) 0.19 (0.13, 0.27)    0.13 (0.04, 0.21)  0.15 (0.10, 0.22) 0.10 (0.06, 0.17)  -0.05 (-0.12, 0.03)  
12 months 0.20 (0.14, 0.28) 0.37 (0.29, 0.46)    0.17 (0.06, 0.28)  0.29 (0.22, 0.38) 0.28 (0.21, 0.37)  -0.01 (-0.12, 0.10)  
24 months 0.53 (0.43, 0.62) 0.63 (0.54, 0.72)   0.11 (-0.02, 0.23)  0.56 (0.47, 0.66) 0.59 (0.50, 0.69)   0.03 (-0.10, 0.16)  
36 months 0.63 (0.54, 0.73) 0.69 (0.60, 0.78)   0.06 (-0.06, 0.21)  0.66 (0.57, 0.75) 0.67 (0.58, 0.76)   0.01 (-0.13, 0.15)  
48 months 0.77 (0.68, 0.85) 0.76 (0.67, 0.84)  -0.01 (-0.14, 0.13)  0.73 (0.63, 0.82) 0.81 (0.71, 0.88)   0.08 (-0.06, 0.20)  
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Panel: Research in context 
Evidence before this studyWe searched PubMed on 25/6/2015 for articles on studies of the effects of dementia drug treatments on nursing home 
placement using the following terms: “Alzheimer’s treatment” AND “Nursing home placement” and “Alzheimer’s treatment” AND “Care home placement” 
and “Cholinesterase inhibitor” AND “Placement”. We identified a single double-blind randomised controlled trial that demonstrated no effect of donepezil 
treatment on nursing home placement in mild to moderate Alzheimer’s disease and 11 open treatment or retrospective analyses that reported apparent 
delayed nursing home placement in patients taking cholinesterase inhibitor treatment. 
Added value of this study 
We showed that moderately-to-severely affected Alzheimer’s disease patients who continued donepezil treatment were at reduced risk of nursing home 
placement during the 12-months of a randomised double-blind controlled trial. Benefits were not maintained after 12 months at which point the patients’ 
treating physicians chose their treatment. Although our results should be considered exploratory as nursing home placement was a secondary outcome and 
analysis restricted to the first 12 months of follow-up was not pre-specified in the analysis plan, they indicate that along with cognitive and functional 
benefits, continuing cholinesterase inhibitor treatment is associated with advantages in maintaining independent home living. 
Implications of all the available evidence 
Because the symptomatic benefits associated with cholinesterase inhibitor treatment in Alzheimer’s disease are modest, it is difficult for physicians to 
evaluate whether their patients are deriving benefit from treatment and they may consider stopping treatment because of perceived lack of efficacy once 
patients have become moderately to severely affected. The evidence suggests that withdrawal of cholinesterase inhibitor treatment is associated with 
worse cognitive and functional outcomes and, from this study, earlier transfer to a nursing home. Decisions to continue or stop treatment in patients with 
moderate and severe Alzheimer’s disease should be made after consideration of these risks.  
 
